PTEN and PI3K/AKT in non-small-cell lung cancer

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer deaths worldwide. In the last years, the identification of activating mutations, conferring increased sensitivity and disease response to tyrosine kinase inhibitors, has changed the prospect of NSCLC patients. The PTEN/PI3K/AKT pathwa...

Full description

Saved in:

Bibliographic Details
Published in:	Pharmacogenomics Vol. 16; no. 16; pp. 1843 - 1862
Main Authors:	Pérez-Ramírez, Cristina, Cañadas-Garre, Marisa, Molina, Miguel Ángel, Faus-Dáder, María José, Calleja-Hernández, Miguel Ángel
Format:	Journal Article
Language:	English
Published:	England Future Medicine Ltd 01-11-2015
Subjects:	1-Phosphatidylinositol 3-kinase AKT protein Animals Antineoplastic Agents - therapeutic use Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Cell adhesion & migration Cell differentiation Cell growth Cell survival Chemotherapy EGFR Enzyme inhibitors Epidermal growth factor receptors Epigenesis, Genetic - genetics Genes Humans Kinases Leukemia Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Mutation Non-small cell lung carcinoma NSCLC pharmacogenetics Phosphatase Phosphatidylinositol 3-Kinases - genetics PI3K Protein-tyrosine kinase Proteins Proto-Oncogene Proteins c-akt - genetics PTEN PTEN Phosphohydrolase - genetics PTEN protein resistance Small cell lung carcinoma Stem cells TKI Tumorigenesis Women United States > US TKI NSCLC PI3K PTEN EGFR pharmacogenetics resistance
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Non-small-cell lung cancer (NSCLC) is the leading cause of cancer deaths worldwide. In the last years, the identification of activating mutations, conferring increased sensitivity and disease response to tyrosine kinase inhibitors, has changed the prospect of NSCLC patients. The PTEN/PI3K/AKT pathway regulates multiple cellular functions, including cell growth, differentiation, proliferation, survival, motility, invasion and intracellular trafficking. Alterations in this pathway, mainly PTEN inactivation, have been associated with resistance to EGFR-tyrosine kinase inhibitor therapy and lower survival in NSCLC patients. In this review, we will briefly discuss the main PTEN/PI3K/AKT pathway alterations found in NSCLC, as well as the cell processes regulated by PTEN/PI3K/AKT leading to tumorigenesis.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	1462-2416 1744-8042
DOI:	10.2217/pgs.15.122